Oncology Panel To Determine Whether Abraxane Needs Randomized Trial In Adjuvant Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The committee will consider if previous studies of Bristol’s Taxol, which has the same active ingredient as Abraxane, are sufficient to support approval via the 505(b)(2) pathway.